Sean David to Receptors, Dopamine D2
This is a "connection" page, showing publications Sean David has written about Receptors, Dopamine D2.
Connection Strength
0.725
-
Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. Nicotine Tob Res. 2007 12; 9(12):1251-7.
Score: 0.287
-
Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? Nicotine Tob Res. 2003 Dec; 5(6):935-42.
Score: 0.218
-
Association of the DRD2 gene Taq1A polymorphism and smoking behavior: a meta-analysis and new data. Nicotine Tob Res. 2009 Jan; 11(1):64-76.
Score: 0.078
-
A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation. Nicotine Tob Res. 2008 Jan; 10(1):231-40.
Score: 0.072
-
Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res. 2007 Aug; 9(8):821-33.
Score: 0.070